Hypera S.A. (HYPMY)
| Market Cap | 3.01B |
| Revenue (ttm) | 1.31B |
| Net Income (ttm) | 154.60M |
| Shares Out | n/a |
| EPS (ttm) | 0.24 |
| PE Ratio | 19.46 |
| Forward PE | 9.35 |
| Dividend | 0.14 (2.76%) |
| Ex-Dividend Date | Dec 30, 2025 |
| Volume | 688 |
| Average Volume | 3,196 |
| Open | 4.750 |
| Previous Close | 5.040 |
| Day's Range | 4.666 - 4.800 |
| 52-Week Range | 3.040 - 5.180 |
| Beta | 0.19 |
| RSI | 59.70 |
| Earnings Date | Mar 12, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]
Full Company ProfileFinancial Performance
In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.
Financial numbers in BRL Financial StatementsNews
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Breno Pires de Oliveira - Chief Executive Officer Ramon Frutuoso Silva - CFO & Investor Relation Offi...
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto...
Hypera: Short-Term Pain For Long-Term Gain
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caus...
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio
In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side Analys...
A Brazilian-Focused Dividend Portfolio
Four out of thirty-seven Brazilian ADRs scored five out of five on the dividend binomial test and they have an equalweight average 2022 forward dividend yield of 7.6%.